Indication
JAK2 V617F
1 clinical trial
2 products
Clinical trial
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative NeoplasmsStatus: Recruiting, Estimated PCD: 2027-07-13
Product
Direct Oral AnticoagulantsProduct
Aspirin